Latest California Healthline Stories
FDA Seeks a New Way to Review Old Drugs Without Causing Prices to Soar
A misguided federal program called the Unapproved Drugs Initiative, which put the FDA’s stamp of approval on old drugs, led to higher prices. It’s scrapped. So now what?
KHN’s ‘What the Health?’: Planning for Round Two
The ink is barely dry on the recent covid relief bill, but Democrats in Congress and President Joe Biden are wasting no time gearing up for their next big legislative package. Meanwhile, predictions of more states expanding Medicaid have proved premature. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat and Kimberly Leonard of Business Insider join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN’s Lauren Weber, who reported the latest KHN-NPR “Bill of the Month” episode.
KHN’s ‘What the Health?’: Getting Down to Work at HHS
After a bruising confirmation process, Xavier Becerra was sworn in as secretary of Health and Human Services this week. The Senate also confirmed the nominations of former U.S. Surgeon General Vivek Murthy to return to the post he held in the Obama administration, and former Pennsylvania health secretary Rachel Levine as assistant secretary for health. Levine is the first openly transgender person to receive Senate confirmation. Meanwhile, questions continue to swirl around the AstraZeneca covid vaccine, which some public health experts worry will create more hesitancy toward other vaccines.
Democrats Eye Medicare Negotiations to Lower Drug Prices
Progressive and conservative Democratic lawmakers, as well as President Joe Biden, are in favor of authorizing federal officials to negotiate with drugmakers over what Medicare pays for at least some of the most expensive brand-name drugs and to base those prices on the drugs’ clinical benefits. Such a measure could put Republicans in the uncomfortable position of opposing an idea that most voters from both parties generally support.
As Drug Prices Keep Rising, State Lawmakers Propose Tough New Bills to Curb Them
The measures would impose taxes on increases in the price of drugs that don’t reflect improved clinical value and set the rates paid by state-run and commercial health plans to a benchmark based on prices in Canada.
States Move Ahead With Canada Drug Importation While Awaiting Signal From Biden
As president, Donald Trump encouraged states to bring in drugs from Canada, where prices are cheaper. It’s not clear if the new administration will follow suit.
With U.S. cases skyrocketing, demand for Gilead’s dark horse antiviral is only growing. Biden appointees propose potential legal tactics to tamp down the price for patients.
Health Issues Carried Weight on the Campaign Trail. What Could Biden Do in His First 100 Days?
KHN has teamed up with PolitiFact to track what becomes of President Joe Biden’s 2020 campaign promises over the next four years. As he moves into the West Wing, what are his chances of making progress on health care?
Even With Senate Control, Democrats Will Need Buy-In From GOP on Key Health Priorities
With a majority too small to eliminate the filibuster, Democrats will not have enough votes in the Senate to pass many of their plans without Republicans and will also have only a razor-thin majority in the House. This combination could doom many Democratic health care proposals, like offering Americans a government-sponsored public insurance option, and complicate efforts to pass further pandemic relief.
Aunque controlen el Senado, demócratas necesitarán apoyo republicano en temas clave de salud
Con el control del Senado y la Cámara de Representantes, tendrán el poder de elegir qué propuestas de salud se votarán en el Congreso. Pero no será tan fácil.